抗生物質：各種技術と世界の市場

世界の抗生物質の市場規模は、2022年の404億米ドルから、2022年から2027年にかけて4.2%のCAGRで推移し、2027年には496億米ドルの規模に成長すると予測されています。

細胞壁阻害剤の部門は、2022年の213億米ドルから、3.9％のCAGRで推移し、2027年には259億米ドルの規模に成長すると予測されています。また、その他のタイプの部門は、2022年の19億米ドルから、7.3%のCAGRで推移し、2027年には28億米ドルの規模に成長すると予測されています。

当レポートでは、世界の抗生物質の市場を調査し、市場および技術の背景、市場影響因子と市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、法規制シナリオ、パイプラインの動向、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場および技術の背景

• 抗生物質の概要
• 抗生物質の一般的な副作用
• 抗生物質の分類
• 細胞壁阻害剤
• タンパク質阻害剤
• DNA阻害剤
• 他の抗生物質クラス
• 抗生物質の分類：供給源別
• グラム陰性菌とグラム陽性菌の概要
• 投与経路
• 抗生物質市場の動向
• 新しい抗生物質の開発
• 抗生物質の医薬品開発：小規模製薬会社
• 官民提携の拡大

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会

第5章 市場内訳：製品別

• 細胞壁阻害剤
• タンパク質阻害剤
• DNA阻害剤
• その他

第6章 市場内訳：投与経路別

• 経口抗生物質
• 局所抗生物質
• その他

第7章 市場内訳：地域別

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 COVID-19が製薬業界に与える影響

第9章 臨床開発とパイプライン製品

• 気道感染症

第10章 バリューチェーン分析

第11章 規制シナリオ

第12章 競合情勢

• 企業シェア分析
• 合併・提携・協力・買収

第13章 企業プロファイル

• ABBOTT
• F. HOFFMANN-LA ROCHE AG
• GLAXOSMITHKLINE PLC
• JOHNSON & JOHNSON
• MERCK & CO. INC.
• PFIZER INC.
• SANOFI
• VIATRIS INC.

第14章 付録：頭字語

List of Tables

• Summary Table A : Global Market for Antibiotics, by Product, Through 2027
• Summary Table B : Global Market for Antibiotics, by Route of Administration, Through 2027
• Table 1 : Major Differences, Gram-Positive and Gram-Negative Organisms
• Table 2 : Proportion of Resistant Strains, by WHO Region
• Table 3 : Global Market for Antibiotics, by Product, Through 2027
• Table 4 : Global Market for Cell Wall Inhibitor, by Product, Through 2027
• Table 5 : Global Market for Cell Wall Inhibitors, by Region, Through 2027
• Table 6 : Global Market for Protein Inhibitors, by Product, Through 2027
• Table 7 : Global Market for Protein Inhibitors, by Region, Through 2025
• Table 8 : Global Market for DNA Inhibitors, by Product, Through 2027
• Table 9 : Global Market for DNA Inhibitors, by Region, Through 2027
• Table 10 : Global Market for Other Types of Inhibitors, by Region, Through 2027
• Table 11 : Global Market for Antibiotics, by Route of Administration, Through 2027
• Table 12 : Global Market for Antibiotics, by Region, Through 2027
• Table 13 : North American Market for Antibiotics, by Product, Through 2027
• Table 14 : North American Market for Antibiotics, by Country, Through 2027
• Table 15 : European Market for Antibiotics, by Product, Through 2025
• Table 16 : European Market for Antibiotics, by Country, Through 2025
• Table 17 : Asia-Pacific Market for Antibiotics, by Product, Through 2027
• Table 18 : Asia-Pacific Market for Antibiotics, by Country, Through 2027
• Table 19 : Latin American Market for Antibiotics, by Product, Through 2027
• Table 20 : Latin American Market for Antibiotics, by Country, Through 2025
• Table 21 : Middle Eastern and African Market for Antibiotics, by Product, Through 2027
• Table 22 : Middle Eastern and African Market for Antibiotics, by Country, Through 2027
• Table 23 : Antibiotics and Combinations in Global Clinical Development, Recent Approvals,2023
• Table 24 : FDA-approved Antibacterial Drugs, 2018
• Table 25 : FDA-Approved Antibacterial Drugs, 2019
• Table 26 : Abbott: Antibiotics Product Portfolio
• Table 27 : F. Hoffmann-La Roche AG: Antibiotics Product Portfolio
• Table 28 : GlaxoSmithKline Plc: Antibiotics Product Portfolio
• Table 29 : Johnson & Johnson: Antibiotics Product Portfolio
• Table 30 : Merck & Co. Inc.: Antibiotics Product Portfolio
• Table 31 : Merck & Co. Inc.: Antibiotic Drug Overview
• Table 32 : Pfizer Inc.: Antibiotics Product Portfolio
• Table 33 : Sanofi: Antibiotics Product Portfolio
• Table 34 : Sanofi S.A.: Antibiotic Drugs Overview
• Table 35 : Vitaris Inc.: Antibiotics Product Portfolio
• Table 36 : Acronyms Used in this Report

List of Figures

• Summary Figure A : Global Market Shares of Antibiotics, by Product, 2021
• Summary Figure B : Global Market Shares of Antibiotics, by Route of Administration, 2021
• Figure 1 : Types of Antibiotics, by Origin Source
• Figure 2 : Share of API Manufacturing Facilities for All Drugs, by Country/Region, Aug. 2019
• Figure 3 : Share of Population Aged 65+, by Region, 2019
• Figure 4 : Forecasted Share of Population Aged 65+, by Region, 2050
• Figure 5 : Increase in Elder Population, 2011 and 2050
• Figure 6 : Distribution of Population with Hospital-acquired Infections, U.S., 2020
• Figure 7 : Socioeconomic and Political Factors Contributing to Antibiotic Resistance
• Figure 8 : Global Market Shares of Antibiotics, by Product, 2021
• Figure 9 : Global Market Shares of Cell Wall Inhibitors, by Product, 2021
• Figure 10 : Global Market for Cell Wall Inhibitors, by Region, 2021-2027
• Figure 11 : Global Market Shares of Protein Inhibitors, by Product, 2021
• Figure 12 : Global Market for Protein Inhibitors, by Region, 2019-2027
• Figure 13 : Global Market Shares of DNA Inhibitors, by Product, 2019
• Figure 14 : Global Market for DNA Inhibitors, by Region, 2019-2027
• Figure 15 : Global Market for Other Types of Inhibitors, by Region, 2019-2027
• Figure 16 : Global Market Shares of Antibiotics, by Route of Administration, 2021
• Figure 17 : Global Market Shares of Antibiotics, by Region, 2021
• Figure 18 : North American Market Shares of Antibiotics, by Product, 2021
• Figure 19 : North American Market Shares of Cell Wall Inhibitors, by Product, 2021
• Figure 20 : North American Market Shares of Protein Inhibitors, by Product, 2021
• Figure 21 : North American Market Shares of DNA Inhibitors, by Product, 2021
• Figure 22 : North American Market Shares of Antibiotics, by Country, 2022
• Figure 23 : U.S. Market for Antibiotics, 2019-2027
• Figure 24 : Canadian Market for Antibiotics, 2019-2027
• Figure 25 : Mexican Market for Antibiotics, 2019-2027
• Figure 26 : European Market Shares of Antibiotics, by Product, 2021
• Figure 27 : European Market Shares of Cell Wall Inhibitors, by Product, 2021
• Figure 28 : European Market Shares of Protein Inhibitors, by Product, 2021
• Figure 29 : European Market Shares of DNA Inhibitors, by Product, 2021
• Figure 30 : European Market Shares of Antibiotics, by Country, 2021
• Figure 31 : German Market for Antibiotics, 2019-2027
• Figure 32 : French Market for Antibiotics, 2019-2027
• Figure 33 : U.K. Market for Antibiotics, 2019-2027
• Figure 34 : Italian Market for Antibiotics, 2019-2027
• Figure 35 : Spanish Market for Antibiotics, 2019-2027
• Figure 36 : Rest of European Market for Antibiotics, 2019-2027
• Figure 37 : Asia-Pacific Market Shares of Antibiotics, by Product, 2021
• Figure 38 : Asia-Pacific Market Shares of Cell Wall Inhibitors, by Product, 2021
• Figure 39 : Asia-Pacific Market Shares of Protein Inhibitors, by Product, 2021
• Figure 40 : Asia-Pacific Market Shares of DNA Inhibitors, by Product, 2021
• Figure 41 : Asia-Pacific Market Shares of Antibiotics, by Country, 2021
• Figure 42 : Japanese Market for Antibiotics, 2019-2027
• Figure 43 : Chinese Market for Antibiotics, 2019-2027
• Figure 44 : Indian Market for Antibiotics, 2019-2027
• Figure 45 : Australia and New Zealand Market for Antibiotics, 2019-2027
• Figure 46 : Rest of Asia-Pacific Market for Antibiotics, 2019-2027
• Figure 47 : Latin American Market Shares of Antibiotics, by Product, 2021
• Figure 48 : Latin American Market Shares of Cell Wall Inhibitors, by Product, 2021
• Figure 49 : Latin American Market Shares of Protein Inhibitors, by Product, 2021
• Figure 50 : Latin American Market Shares of DNA Inhibitors, by Product, 2021
• Figure 51 : Latin American Market Shares of Antibiotics, by Country, 2021
• Figure 52 : Brazilian Market for Antibiotics, 2019-2027
• Figure 53 : Argentinian Market for Antibiotics, 2019-2027
• Figure 54 : Rest of Latin American Market for Antibiotics, 2019-2027
• Figure 55 : Middle Eastern and African Market Shares of Antibiotics, by Product, 2021
• Figure 56 : Middle Eastern and African Market Shares of Cell Wall Inhibitors, by Product, 2021
• Figure 57 : Middle Eastern and African Market Shares of Protein Inhibitors, by Product, 2021
• Figure 58 : Middle Eastern and African Market Shares of DNA Inhibitors, by Product, 2021
• Figure 59 : Middle Eastern and African Market Shares of Antibiotics, by Country, 2021
• Figure 60 : GCC Countries' Market for Antibiotics , 2019-2027
• Figure 61 : South African Market for Antibiotics, 2021-2027
• Figure 62 : Rest of Middle Eastern and African Market for Antibiotics, 2019-2027
• Figure 63 : Impact of COVID-19 on the Pharmaceutical Industry
• Figure 64 : Value Chain Analysis
• Figure 65 : Global Market Shares of Antibiotics, by Manufacturer, 2021
• Figure 66 : Abbott: Annual Revenue, 2019-2021
• Figure 67 : Abbott: Revenue Shares, by Country/Region, 2021
• Figure 68 : Abbott: Revenue Shares, by Business Unit, 2021
• Figure 69 : F. Hoffmann-La Roche AG: Annual Revenue, 2019-2022
• Figure 70 : F. Hoffmann-La Roche AG: Revenue Shares in Pharmaceutical Segment, by Country/Region, 2022
• Figure 71 : F. Hoffmann-La Roche AG: Revenue Shares, by Business Segment, 2022
• Figure 72 : F. Hoffmann-La Roche AG: Revenue Shares, by Therapeutic Segment, 2022
• Figure 73 : GlaxoSmithKline Plc: Annual Revenue, 2020-2022
• Figure 74 : GlaxoSmithKline Plc: Revenue Shares, by Pharmaceutical, 2022
• Figure 75 : GlaxoSmithKline Plc: Revenue Shares, by Product Category, 2022
• Figure 76 : GlaxoSmithKline Plc: Revenue Shares, by Region, 2022
• Figure 77 : Johnson & Johnson: Annual Revenue, 2019-2021
• Figure 78 : Johnson & Johnson: Revenue Shares, by Region, 2021
• Figure 79 : Johnson & Johnson: Revenue Shares, by Business Unit, 2021
• Figure 80 : Merck & Co. Inc.: Annual Revenue, 2020-2022
• Figure 81 : Merck & Co. Inc.: Revenue Shares, by Region, 2019
• Figure 82 : Merck & Co. Inc.: Revenue Shares, by Business Unit, 2019
• Figure 83 : Pfizer Inc.: Annual Revenue, 2020-2022
• Figure 84 : Pfizer Inc.: Revenue Shares, by Region, 2022
• Figure 85 : Pfizer Inc.: Revenue Shares, by Country, 2022
• Figure 86 : Pfizer Inc.: Revenue Shares, by Business Segment, 2022
• Figure 87 : Sanofi: Annual Revenue, 2020-2022
• Figure 88 : Sanofi: Revenue Shares, by Region/Country, 2022
• Figure 89 : Sanofi: Revenue Shares, by Business Segment, 2022
• Figure 90 : Viatris Inc.: Annual Revenue, 2020-2022
• Figure 91 : Vitaris Inc.: Revenue Shares, by Region, 2022
• Figure 92 : Vitaris Inc.: Revenue Shares, by Business Unit, 2022

Highlights:

The global antibiotics market reached $40.4 billion in 2022 and should reach $49.6 billion by 2027, with a compound annual growth rate (CAGR) of 4.2% during the forecast period of 2022-2027.

Cell wall inhibitor segment of the global antibiotics market reached $21.3 billion in 2022 and should reach $25.9 billion by 2027, with a CAGR of 3.9% during the forecast period of 2022-2027.

Other types segment of the global antibiotics market reached $1.9 billion in 2022 and should reach $2.8 billion by 2027, with a CAGR of 7.3% during the forecast period of 2022-2027.

Report Scope:

This report is focused on newer drugs and innovations in chemical compounds, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control, drugs used for symptomatic treatment and not for the elimination of the virus from the host and details on manufacturers and suppliers of non-branded generics. This report will also highlight the current and future market potential of antibiotics with detailed analysis of the competitive environment. Drivers, restraints, opportunities, pricing analysis, impact of COVID-19, other infectious diseases and a regulatory scenario assessment are covered, along with a market projection for 2027 and market share assessment for key players.

The report segments the market for antibiotics based on product type, route of administration, application and geographical region. Based on product type, the market is segmented into cell wall inhibitors, protein inhibitors, DNA and other inhibitors (RNA, mycolic acid, folic acid). Based on route of administration, the market is segmented into oral and topical.

By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, South America and the Middle East and Africa. Detailed analysis of major countries (U.S., Germany, UK, Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa) will be covered in the regional segment. For market estimates, data will be provided for 2021 as the base year, with estimates for 2022 and forecast value for 2027.

Report Includes:

• 22 data tables and 16 additional tables
• An overview of the global market for antibiotics within the pharmaceutical industry
• Analyses of the global market trends, with data corresponding to market size for 2019-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2027
• Information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace
• Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user, and geographical region
• Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa
• Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances
• Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc. and Sanofi

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Information Sources
• Methodology
• Geographic Breakdown
• Analyst's Credentials
• BCC Custom Research
• Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

• Overview of Antibiotics
• Common Side Effects of Antibiotics
• Classification of Antibiotics
• Cell Wall Inhibitors
• Protein Inhibitors
• DNA Inhibitors
• Other Antibiotic Classes
• Antibiotic Classification, by Source
• Overview of Gram-Negative and Gram-Positive Bacteria
• Route of Administration
• Trends in the Market for Antibiotics
• New Antibiotic Development
• Antibiotic Drug Development, Smaller Pharmaceutical Firms
• Growing Public/Private Partnerships

Chapter 4 Market Dynamics

• Market Drivers
• Growth Driven by Antibiotics
• Rising Elder Population and Infection Rate
• Increasing Hospital-acquired Infections
• Improved Awareness
• Market Restraints
• Antibiotic-resistant Infections
• Generics
• Declining R&D Investment
• Side Effects of Antibiotics
• Market Opportunities
• Market Expansion
• Novel Antibacterial Agents

Chapter 5 Market Breakdown, by Product

• Global Market for Antibiotics by Product
• Cell Wall Inhibitors
• Protein Inhibitors
• DNA Inhibitors
• Other Types of Inhibitors

Chapter 6 Market Breakdown, by Route of Administration

• Global Market for Antibiotics by Route of Administration
• Oral Antibiotics
• Topical Antibiotics
• Other Routes of Administration

Chapter 7 Market Breakdown, by Region

• Global Market for Antibiotics by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Chapter 8 Impact of COVID-19 on the Pharmaceutical Industry

• Short-term Impact
• Change in Demand
• Shift of Communication and Promotions to Remote Interactions
• R&D Changes
• Long-term Impact
• Delayed Approvals for Non-COVID-related Pharmaceutical Products
• Self-sufficiency in Pharma
• Pharmaceutical Industry Growth Slowdown
• Changes in Consumption Trends in Health-related Products

Chapter 9 Clinical Developments and Pipeline Products

• Respiratory Tract Infections

Chapter 10 Value Chain Analysis

• Introduction
• China: Center of Microbial Threat

Chapter 11 Regulatory Scenario

• FDA and International Regulation
• Recent Regulatory Reforms
• Ketek Case Study

Chapter 12 Competitive Landscape

• Global Company Market Share Analysis
• Mergers, Collaborations, Partnerships and Acquisitions

Chapter 13 Company Profiles

• ABBOTT
• F. HOFFMANN-LA ROCHE AG
• GLAXOSMITHKLINE PLC
• JOHNSON & JOHNSON
• MERCK & CO. INC.
• PFIZER INC.
• SANOFI
• VIATRIS INC.

Chapter 14 Appendix: Acronyms